Dave Ricks
Chair & CEO, Eli Lilly
“The Medicare GLP-1 Bridge Program launched on July 1, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity at the low out-of-pocket price of $50 per month. With this expansion, 35% more people now have coverage for our obesity medicines in the United States.”
“We continued our manufacturing build-out and opened our first dedicated genetic medicine manufacturing facility in Lebanon, Indiana. We also produced the first batch of commercial material at our new manufacturing site in Limerick, Ireland.”
“we believe retatrutide is a biologic application, both in terms of amino acid count rule as well as analogous to a protein.”
Dave Ricks
One-line summary: Chair and CEO of eli-lilly; states Lilly's own demand-side mechanisms on earnings calls (Medicare GLP-1 Bridge, manufacturing build-out).
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On glp1-injectable-supply-chain-bottleneck, glp1-substitution-to-bariatric-surgery-decline:
"The Medicare GLP-1 Bridge Program launched on July 1, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity at the low out-of-pocket price of $50 per month. With this expansion, 35% more people now have coverage for our obesity medicines in the United States." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
-
On glp1-injectable-supply-chain-bottleneck:
"We continued our manufacturing build-out and opened our first dedicated genetic medicine manufacturing facility in Lebanon, Indiana. We also produced the first batch of commercial material at our new manufacturing site in Limerick, Ireland." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
-
On glp1-substitution-to-bariatric-surgery-decline:
"we believe retatrutide is a biologic application, both in terms of amino acid count rule as well as analogous to a protein." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
Sources
Related
Cross-links — fill in.